1H magnetic resonance spectroscopy in dementia

British Journal of Radiology

Volumn 80, Issue SPEC. ISS. 2, 2007, Pages

  Kantarci, Kejal ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATINE; CREATININE; INOSITOL; N ACETYLASPARTIC ACID;

AGING; ALZHEIMER DISEASE; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FRONTOTEMPORAL DEMENTIA; HUMAN; IN VIVO STUDY; LEWY BODY; MULTIINFARCT DEMENTIA; PATIENT MONITORING; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; CLINICAL ASSESSMENT; EARLY DIAGNOSIS; HISTOPATHOLOGY; NEUROIMAGING; PREDICTION; DIFFUSE LEWY BODY DISEASE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ALZHEIMER DISEASE; DEMENTIA; DEMENTIA, VASCULAR; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; LEWY BODY DISEASE; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 43549126232     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/60346217     Document Type: Review

References (73)

1. Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, Rapoport SI, et al. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology 2001;57:626-32.
2. Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000;55:684-8.
3. Klunk WE, Panchalingam K, McClure RJ, Stanley JA, Pettegrew JW. Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4. Neurobiol Aging 1998;19:511-15.
4. Meyerhoff DJ, MacKay S, Constans JM, Norman D, Van Dyke C, Fein G, et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol 1994;36:40-7.
5. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: depiction of increased cerebral myoinositol with proton MR spectroscopy. Radiology 1993;187:433-7.
6. Mohanakrishnan P, Fowler AH, Vonsattel JP, Jolles PR, Husain MM, Liem P, et al. Regional metabolic alterations in Alzheimer's disease: an in vitro 1H NMR study of the hippocampus and cerebellum. J Gerontol Series A Biol Sci Med Sci 1997;52:B111-17.
7. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med 1999;41:276-84.
8. Rose SE, de Zubicaray GI, Wang D, Galloway GJ, Chalk JB, Eagle SC, et al. A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 1999;17:291-9.
9. Schuff N, Capizzano AA, Du AT, Amend DL, O'Neill J, Norman D, et al. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 2002;58:928-35.
10. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. [see comment]. Radiology 1995;195:65-72.
11. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, et al. 1H MR spectroscopy in common dementias. Neurology 2004;63:1393-8.
12. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003;160:2003-11.
13. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994;32:110-15.
14. Parnetti L, Tarducci R, Presciutti O, Lowenthal DT, Pippi M, Palumbo B, et al. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 1997;97:9-14.
15. Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 1997;49:1513-21.
16. Petrovitch H, White LR, Ross GW, Steinhorn SC, Li CY, Masaki KH, et al. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. [see comment]. Neurology 2001;57:226-34.
17. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997;203:829-36.
18. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 1996;7:1397-400.
19. Brooks WM, Stidley CA, Petropoulos H, Jung RE, Weers DC, Friedman SD, et al. Metabolic and cognitive response to human traumatic brain injury: a quantitative proton magnetic resonance study. J Neurotrauma 2000;17:629-40.
20. Bendszus M, Reents W, Franke D, Mullges W, Babin-Ebell J, Koltzenburg M, et al. Brain damage after coronary artery bypass grafting. Arch Neurol 2002;59:1090-5.
21. Hugg JW, Kuzniecky RI, Gilliam FG, Mora wetz RB, Fraught RE, Hetherington HP. Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic resonance spectroscopic imaging. Ann Neurol 1996;40:236-9.
22. Modrego PJ, Pina MA, Fayed N, Diaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 2006;20:867-77.
23. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
24. Kantarci K, Jack CR, Jr, Xu YC, Campeau NG, O'Brien PC, Smith GE, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000;55:210-17.
25. Zhu X, Schuff N, Kornak J, Soher B, Yaffe K, Kramer JH, et al. Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 2006;20:77-85.
26. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 2000;107:1027-63.
27. MacKay S, Meyerhoff DJ, Constans JM, Norman D, Fein G, Weiner MW. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol 1996;53:167-74.
28. Wurtman RJBJ, Marie JC. Autocannibalism of choline-containing membrane phospholipids in the pathogenesis of Alzheimer's disease. Neurochem Int 1985;369-72.
29. Satlin A, Bodick N, Offen WW, Renshaw PF. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry 1997;154:1459-61.
30. Glanville NT, Byers DM, Cook HW, Spence MW, Palmer FB. Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochim Biophys Acta 1989;1004:169-79.
31. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am J Neuroradiol 1999;20:1619-27.
32. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Tan J. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am 1998;8:809-22.
33. Soher BJ, Vermathen P, Schuff N, Wiedermann D, Meyerhoff DJ, Weiner MW, et al. Short TE in vivo (1)H MR spectroscopic imaging at 1.5 T: acquisition and automated spectral analysis. Magn Reson Imaging 2000;18:1159-65.
34. Doraiswamy PM, Charles HC, Krishnan KR. Prediction of cognitive decline in early Alzheimer's disease. Lancet 1998;352:1678.
35. Kantarci K, Smith GE, Ivnik RJ, Petersen RC, Boeve BF, Knopman DS, et al. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 2002;8:934-42.
36. Kwo-On-Yuen PF, Newmark RD, Budinger TF, Kaye JA, Ball MJ, Jagust WJ. Brain N-acetyl-L-aspartic acid in Alzheimer's disease: a proton magnetic resonance spectroscopy study. Brain Res 1994;667:167-74.
37. Schuff N, Amend DL, Meyerhoff DJ, Tanabe JL, Norman D, Fein G, et al. Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology 1998;207:91-102.
38. Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 2004;1003:26-35.
39. Fernandez A, Garcia-Segura JM, Ortiz T, Montoya J, Maestu F, Gil-Gregorio P, et al. Proton magnetic resonance spectroscopy and magnetoencephalographic estimation of delta dipole density: a combination of techniques that may contribute to the diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20:169-77.
40. Kantarci K, Xu Y, Shiung MM, O'Brien PC, Cha RH, Smith GE, et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 2002;14:198-207.
41. Martinez-Bisbal MC, Arana E, Marti-Bonmati L, Molla E, Celda B. Cognitive impairment: classification by 1H magnetic resonance spectroscopy. Eur J Neurol 2004;11:187-93.
42. MacKay S, Ezekiel F, Di Sclafani V, Meyerhoff DJ, Gerson J, Norman D, et al. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 1996;198:537-45.
43. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. [see comment]. Neurology 2001;56:1143-53.
44. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse, [see comment]. Nature 1999;400:173-7.
45. Kordower JH, Chu Y, Stebbins GT, DeKosky ST, Cochran EJ, Bennett D, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001;49:202-13.
46. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94.
47. Catani M, Cherubini A, Howard R, Tarducci R, Pelliccioli GP, Piccirilli M, et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001;12:2315-17.
48. Huang W, Alexander GE, Daly EM, Shetty HU, Krasuski JS, Rapoport SI, et al. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. Am J Psychiatry 1999;156:1879-86.
49. Shonk T, Ross BD. Role of increased cerebral myo-inositol in the dementia of Down syndrome. Magn Reson Med 1995;33:858-61.
50. Ackl N, Ising M, Schreiber YA, Atiya M, Sonntag A, Auer DP. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2005;384:23-8.
51. Chao LL, Schuff N, Kramer JH, Du AT, Capizzano AA, O'Neill J, et al. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology 2005;64:282-9.
52. Metastasio A, Rinaldi P, Tarducci R, Mariani E, Feliziani FT, Cherubini A, et al. Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiol Aging 2006;27:926-32.
53. Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. [see comment]. Am J Psychiatry 2005;162:667-75.
54. den Heijer T, Sijens PE, Prins ND, Hofman A, Koudstaal PJ, Oudkerk M, et al. MR spectroscopy of brain white matter in the prediction of dementia. Neurology 2006;66:540-4.
55. Godbolt AK, Waldman AD, MacManus DG, Schott JM, Frost C, Cipolotti L, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 2006;66:718-22.
56. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000;355:1696-7.
57. Jessen F, Block W, Traber F, Keller E, Flacke S, Lamerichs R, et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001;57:930-2.
58. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J, et al. Longitudinal (1)H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2007;28:1330-9.
59. Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, Poduslo JF, et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 2005;102:11906-10.
60. Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 2006;67:528-30.
61. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. [see comment]. Br J Psychiatry 1999;174:45-50.
62. Kattapong VJ, Brooks WM, Wesley MH, Kodituwakku PW, Rosenberg GA. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch Neurol 1996;53:678-80.
63. Ross AJ, Sachdev PS, Wen W, Valenzuela MJ, Brodaty H. 1H MRS in stroke patients with and without cognitive impairment. Neurobiol Aging 2005;26:873-82.
64. Waldman AD, Rai GS, McConnell JR, Chaudry M, Grant D. Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch Gerontol Geriatr 2002;35:137-42.
65. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
66. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000;10:378-84.
67. Gomez-Isla T, Growdon WB, McNamara M, Newell K, Gomez-Tortosa E, Hedley-Whyte ET, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999;53:2003-9.
68. Molina JA, Garcia-Segura JM, Benito-Leon J, Gomez-Escalonilla C, del Ser T, Martinez V, et al. Proton magnetic resonance spectroscopy in dementia with Lewy bodies. Eur Neurol 2002;48:158-63.
69. Tiraboschi P, Hansen LA, Alford M, Merdes A, Masliah E, Thal LJ, et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002;59:946-51.
70. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000;15:387-92.
71. Garrard P, Schott JM, MacManus DG, Hodges JR, Fox NC, Waldman AD. Posterior cingulate neurometabolite profiles and clinical phenotype in frontotemporal dementia. Cogn Behav Neurol 2006;19:185-9.
72. Mihara M, Hattori N, Abe K, Sakoda S, Sawada T. Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex. Neuroreport 2006;17:413-16.
73. Kantarci K, Jack CR, Jr. Predicting progression of Alzheimer's disease with magnetic resonance. In: Broderick PA, Rahni DA, Kolodny EH, editors. Bioimaging in Neurodegeneration. Humana Press, 2005.